Comparative Pharmacology
Head-to-head clinical analysis: OXYBUTYNIN versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYBUTYNIN versus VESICARE LS.
OXYBUTYNIN vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxybutynin is an anticholinergic agent that competitively antagonizes muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the bladder detrusor muscle, inhibiting involuntary contractions and increasing bladder capacity.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: 5-10 mg orally once daily; maximum 30 mg/day. Transdermal: 3.9 mg/day patch applied every 3-4 days. Topical gel: 1 g (3 pumps) applied once daily.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Clinical Note
moderateOxybutynin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Fluconazole
Terminal half-life: 12-13 hours (range 7-20 hours) in healthy adults. In elderly, half-life may be prolonged due to reduced clearance.
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are mainly excreted renally (50%) and fecally (40%).
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category A/B
Category C
Anticholinergic
Anticholinergic
"The metabolism of Fluconazole can be decreased when combined with Oxybutynin."